Clarithromycin in 2003: Sustained efficacy and safety in an era of rising antibiotic resistance

Antonio R Anzueto, Sandra Norris

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Data from surveillance studies show increasing prevalence of respiratory pathogens resistant to commonly used antibiotics. Thus, a Medline search was conducted to identify studies of clarithromycin, especially those addressing macrolide resistance. Changing trends of in vitro susceptibility have not affected clinical efficacy with clarithromycin. Over the last 12 years, clarithromycin study results have shown consistent rates of clinical cure and bacteriological eradication, which are similar to those observed with comparator agents. The incidence of clarithromycin treatment failure in patients infected with Streptococcus pneumoniae is substantially less than that predicted by macrolide resistance rates from surveillance programmes. In summary, despite widespread use since its introduction, clarithromycin remains active both in vitro and in vivo against clinically relevant respiratory tract pathogens.

Original languageEnglish (US)
Pages (from-to)1-17
Number of pages17
JournalInternational Journal of Antimicrobial Agents
Volume24
Issue number1
DOIs
StatePublished - Jul 2004

Fingerprint

Clarithromycin
Microbial Drug Resistance
Safety
Macrolides
Streptococcus pneumoniae
Treatment Failure
Respiratory System
Anti-Bacterial Agents
Incidence

Keywords

  • Antibiotic resistance
  • Clarithromycin
  • Respiratory tract infection

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Microbiology
  • Parasitology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Clarithromycin in 2003 : Sustained efficacy and safety in an era of rising antibiotic resistance. / Anzueto, Antonio R; Norris, Sandra.

In: International Journal of Antimicrobial Agents, Vol. 24, No. 1, 07.2004, p. 1-17.

Research output: Contribution to journalArticle

@article{deac9065ce9a49cfb9b78e563e115348,
title = "Clarithromycin in 2003: Sustained efficacy and safety in an era of rising antibiotic resistance",
abstract = "Data from surveillance studies show increasing prevalence of respiratory pathogens resistant to commonly used antibiotics. Thus, a Medline search was conducted to identify studies of clarithromycin, especially those addressing macrolide resistance. Changing trends of in vitro susceptibility have not affected clinical efficacy with clarithromycin. Over the last 12 years, clarithromycin study results have shown consistent rates of clinical cure and bacteriological eradication, which are similar to those observed with comparator agents. The incidence of clarithromycin treatment failure in patients infected with Streptococcus pneumoniae is substantially less than that predicted by macrolide resistance rates from surveillance programmes. In summary, despite widespread use since its introduction, clarithromycin remains active both in vitro and in vivo against clinically relevant respiratory tract pathogens.",
keywords = "Antibiotic resistance, Clarithromycin, Respiratory tract infection",
author = "Anzueto, {Antonio R} and Sandra Norris",
year = "2004",
month = "7",
doi = "10.1016/j.ijantimicag.2004.03.003",
language = "English (US)",
volume = "24",
pages = "1--17",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Clarithromycin in 2003

T2 - Sustained efficacy and safety in an era of rising antibiotic resistance

AU - Anzueto, Antonio R

AU - Norris, Sandra

PY - 2004/7

Y1 - 2004/7

N2 - Data from surveillance studies show increasing prevalence of respiratory pathogens resistant to commonly used antibiotics. Thus, a Medline search was conducted to identify studies of clarithromycin, especially those addressing macrolide resistance. Changing trends of in vitro susceptibility have not affected clinical efficacy with clarithromycin. Over the last 12 years, clarithromycin study results have shown consistent rates of clinical cure and bacteriological eradication, which are similar to those observed with comparator agents. The incidence of clarithromycin treatment failure in patients infected with Streptococcus pneumoniae is substantially less than that predicted by macrolide resistance rates from surveillance programmes. In summary, despite widespread use since its introduction, clarithromycin remains active both in vitro and in vivo against clinically relevant respiratory tract pathogens.

AB - Data from surveillance studies show increasing prevalence of respiratory pathogens resistant to commonly used antibiotics. Thus, a Medline search was conducted to identify studies of clarithromycin, especially those addressing macrolide resistance. Changing trends of in vitro susceptibility have not affected clinical efficacy with clarithromycin. Over the last 12 years, clarithromycin study results have shown consistent rates of clinical cure and bacteriological eradication, which are similar to those observed with comparator agents. The incidence of clarithromycin treatment failure in patients infected with Streptococcus pneumoniae is substantially less than that predicted by macrolide resistance rates from surveillance programmes. In summary, despite widespread use since its introduction, clarithromycin remains active both in vitro and in vivo against clinically relevant respiratory tract pathogens.

KW - Antibiotic resistance

KW - Clarithromycin

KW - Respiratory tract infection

UR - http://www.scopus.com/inward/record.url?scp=3042600593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042600593&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2004.03.003

DO - 10.1016/j.ijantimicag.2004.03.003

M3 - Article

C2 - 15225854

AN - SCOPUS:3042600593

VL - 24

SP - 1

EP - 17

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 1

ER -